Abstract：Objective To examine the expression of serum thyroglobulin antibody (TGAb) and thyroid peroxidase antibody (TPOAb) in children with immune thrombocytopenia (ITP). Methods A total of 120 children with ITP who were admitted from October 2019 to October 2021 were enrolled as the ITP group. A total of 60 children without ITP were enrolled as the non-ITP group. According to the clinical classification of ITP, the children in the ITP group were further divided into a newly diagnosed ITP group, a persistent ITP group, and a chronic ITP group. The clinical data were compared between the ITP group and the non-ITP group and between the children with different clinical classifications of ITP. The expression levels of serum TGAb and TPOAb in children with ITP were measured and their association with the clinical classification of ITP was analyzed. Results Compared with the non-ITP group, the ITP group had significantly lower levels of CD3+, CD4+, and platelet count (PLT) and significantly higher levels of CD8+, TGAb, and TPOAb (P<0.05). The children with chronic ITP had significantly lower levels of CD3+, CD4+, and PLT and significantly higher levels of CD8+, TGAb, and TPOAb than those with newly diagnosed ITP or persistent ITP (P<0.05). The logistic regression analysis showed that CD3+, CD4+, CD8+, TGAb, and TPOAb were the influencing factors for chronic ITP (P<0.05). A decision curve was plotted, and the results showed that TGAb combined with TPOAb within the high-risk threshold range of 0.0-1.0 had a net benefit rate of >0 in evaluating the clinical classification of ITP in children. Conclusions TGAb and TPOAb are abnormally expressed in children with ITP and are associated with the clinical classification of ITP in children.
WANG Xue-Mei,NURIDDIN Hailigulli,LIU Yu et al. Expression of thyroglobulin antibody and thyroid peroxidase antibody in children with immune thrombocytopenia[J]. CJCP, 2022, 24(6): 687-692.
Gallo D, Tanda ML, Piantanida E. Predicting the risk of graves disease relapse: commentary on "thyroid peroxidase antibody positivity is associated with relapse-free survival following antithyroid drug treatment for graves disease"[J]. Endocr Pract, 2020, 26(9): 1039-1041. PMID: 33471693. DOI: 10.4158/EP-2020-0230.
Grace RF, Despotovic JM, Bennett CM, et al. Physician decision making in selection of second-line treatments in immune thrombocytopenia in children[J]. Am J Hematol, 2018, 93(7): 882-888. PMID: 29659042. PMCID: PMC6037544. DOI: 10.1002/ajh.25110.
Fernández-Plaza S, González de Pablo J, Gálvez E, et al. Variables related to chronic immune thrombocytopenia: experience from a single center and comparison to a meta-analysis[J]. Eur J Pediatr, 2021, 180(7): 2075-2081. PMID: 33594540. DOI: 10.1007/s00431-021-03990-8.
Hua M, Li J, Wang C, et al. Aberrant expression of microRNA in CD4+ cells contributes to Th17/Treg imbalance in primary immune thrombocytopenia[J]. Thromb Res, 2019, 177: 70-78. PMID: 30856381. DOI: 10.1016/j.thromres.2019.03.005.
Yao L, Liu B, Jiang L, et al. Association of cytotoxic T-lymphocyte antigen 4 gene with immune thrombocytopenia in Chinese Han children[J]. Hematology, 2019, 24(1): 123-128. PMID: 30319055. DOI: 10.1080/10245332.2018.1530179.
Wang Q, Li J, Yu TS, et al. Disrupted balance of CD4+ T-cell subsets in bone marrow of patients with primary immune thrombocytopenia[J]. Int J Biol Sci, 2019, 15(13): 2798-2814. PMID: 31853219. PMCID: PMC6909963. DOI: 10.7150/ijbs.33779.
Eick GN, Cepon-Robins TJ, Devlin MJ, et al. Development and validation of an ELISA for a biomarker of thyroid dysfunction, thyroid peroxidase autoantibodies (TPO-Ab), in dried blood spots[J]. J Physiol Anthropol, 2020, 39(1): 16. PMID: 32678000. PMCID: PMC7364519. DOI: 10.1186/s40101-020-00228-8.
